argenx sets October 22 results date for argenx stock

Published on 10/19/2026 at 10:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 22, 2026 after second-quarter revenue reached USD 1.54 billion. argenx stock costs EUR 731.60 on October 19, 2026 before the update.

Upcoming results shape the setup

argenx announced its third-quarter update for October 22, 2026.
Second-quarter revenue reached USD 1.54 billion in the reported period.
argenx stock traded at EUR 731.60 at 10:20 a.m. CEST at Lang & Schwarz on October 19, 2026.

Vogelperspektive-Flatlay: Behandschuhte Hände führen Multikanal-Pipette über 96-Well-Mikrotiterplatte mit blauer Flüssigkeit, weißer Labortisch, symmetrische Komposition — Argenx NL0010832176 Mehrkanal-Pipette befüllt von oben eine blaue 96-Well-Platte im Immunologie-Labor sorgfältig, Illustration mit AI erstellt.

argenx (ISIN NL0010832176) set October 22, 2026 for its third-quarter financial results and business update. According to GlobeNewswire, the company will host its conference call at 2:30 p.m. CET, giving investors a near-term checkpoint after a volatile October for the biotechnology group.

October 22 brings the next test

The upcoming release matters because argenx enters it with a large commercial base and a pipeline reshaped by recent clinical news. The company reported second-quarter revenue of USD 1.54 billion and adjusted earnings per share of USD 7.32, compared with a consensus estimate of USD 5.86, according to MarketBeat. Revenue therefore exceeded the cited USD 1.45 billion consensus by USD 90 million.

Three events changed the picture

On July 21, 2026, argenx reported USD 1.54 billion in second-quarter revenue and adjusted earnings per share of USD 7.32. On October 8, 2026, the company discontinued the Phase 3 UNITY study in Sjogren's disease after an interim analysis found that the trial was unable to meet its primary endpoint, according to GlobeNewswire. On October 15, 2026, argenx announced the October 22 reporting date and a business update.

What will the update clarify?

The key issue is whether VYVGART growth can keep carrying the commercial story while investors reassess pipeline execution. BofA raised its price target from USD 1,136 to USD 1,157 on October 12, 2026 and retained a Buy rating, while modeling third-quarter VYVGART revenue of USD 1.63 billion, according to Markets Insider. Wells Fargo separately maintained a Buy rating and set a USD 1,356.00 target on October 14, 2026, according to Markets Insider.

Stock price before the results

For investors, the October 22 update links the near-term valuation to two competing signals: strong VYVGART demand and the setback in Sjogren's disease. The next release can therefore provide a fresh read on product revenue, pipeline priorities and management's assessment of the UNITY outcome.

argenx stock was trading at EUR 731.60 at Lang & Schwarz on October 19, 2026 at 10:20 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of argenx stock.